Actionable news
0
All posts from Actionable news
Actionable news in RNN: REXAHN PHARMACEUTICALS Inc,

Company Update (NYSEMKT:RNN): Rexahn Pharmaceuticals, Inc. Receives U.S. Patent for RX-3117 Anti-Cancer Program

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that it has been issued a U.S. patent from the United States Patent and Trademark Office (USPTO) for claims related to the synthesis of its novel anti-cancer investigational drug candidate, RX-3117. In preclinical studies, RX-3117 has demonstrated broad spectrum anti-tumor activity, notably in human cancer cell lines that have been made resistant to gemcitabine (Gemzar®), a widely-used type of chemotherapy. RX-3117 is currently being evaluated in a Phase Ib clinical trial in cancer patients with solid tumors.

“Rexahn is pleased to expand its intellectual...


More